Silence Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Silence Therapeutics's estimated annual revenue is currently $19.7M per year.
- Silence Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Silence Therapeutics has 127 Employees.
- Silence Therapeutics grew their employee count by -9% last year.
Silence Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP - Information Technology | Reveal Email/Phone |
2 | Head Clinical Quality Assurance | Reveal Email/Phone |
3 | VP, Investor Relations and Corporate Communications | Reveal Email/Phone |
4 | SVP, Chief Intellectual Property and Innovation Officer | Reveal Email/Phone |
5 | VP, Head Clinical Operations | Reveal Email/Phone |
6 | VP, Head HR | Reveal Email/Phone |
7 | SVP, Regulatory Affairs & Quality Assurance | Reveal Email/Phone |
8 | SVP, Head CMC Manufacturing | Reveal Email/Phone |
9 | VP, Group Leader Oligonucleotide Chemistry | Reveal Email/Phone |
10 | VP Drug Discovery | Reveal Email/Phone |
Silence Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 101 | 5% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 470 | 16% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5356 | 8% | N/A | N/A |
What Is Silence Therapeutics?
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassaemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
keywords:N/A
N/A
Total Funding
127
Number of Employees
$19.7M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Silence Therapeutics News
The agent, SLN360 (Silence Therapeutics), is one of several in development to reduce Lp(a), elevated levels of which are a major CVD risk factor...
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to...
Following a single subcutaneous dose of SLN360 (Silence Therapeutics), there was a dose-dependent reduction in Lp(a) plasma levels by a...
Other Companies in London
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.4M | 127 | -4% | $11.5M |
#2 | $26.7M | 127 | 27% | N/A |
#3 | $25.5M | 127 | 28% | N/A |
#4 | $15M | 127 | 9% | N/A |
#5 | $27.9M | 127 | 8% | N/A |